{"id":"cefoselis","rwe":[{"pmid":"40985153","year":"2025","title":"Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies.","finding":"","journal":"The Journal of antimicrobial chemotherapy","studyType":"Clinical Study"},{"pmid":"37184411","year":"2023","title":"In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019.","finding":"","journal":"Microbiology spectrum","studyType":"Clinical Study"},{"pmid":"36808887","year":"2023","title":"Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells.","finding":"","journal":"Clinical and translational medicine","studyType":"Clinical Study"},{"pmid":"34222426","year":"2021","title":"Efficacy of combination of localized closure, ethacridine lactate dressing, and phototherapy in treatment of severe extravasation injuries: A case series.","finding":"","journal":"World journal of clinical cases","studyType":"Clinical Study"},{"pmid":"34215878","year":"2021","title":"Establishment of epidemiological cut-off values for cefoselis, a new fourth-generation cephalosporin, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis and Pseudomonas aeruginosa.","finding":"","journal":"The Journal of antimicrobial chemotherapy","studyType":"Clinical Study"}],"tags":[{"label":"cefoselis","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"wincef","offLabel":[],"synonyms":["cefoselis","wincef","cefoselis sulfate"],"timeline":[],"brandName":"Wincef","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cefoselis","explanation":"Imagine the bacterial cell wall as a brick wall. Wincef blocks the enzymes that help build the wall, causing the wall to weaken and eventually collapse. This makes it difficult for the bacteria to survive and multiply.","oneSentence":"Wincef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","technicalDetail":"Wincef exerts its antibacterial effect by inhibiting the transpeptidase enzymes responsible for cross-linking peptidoglycan chains in the bacterial cell wall, ultimately leading to cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/545","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFOSELIS","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:20:04.932485","biosimilars":[],"competitors":[],"genericName":"cefoselis","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"0B50MLU3H1","CHEBI":"CHEBI:3496","INN_ID":"7171","UMLSCUI":"C0965645","ChEMBL_ID":"CHEMBL2105940","KEGG_DRUG":"D02232","PUBCHEM_CID":"5748845","IUPHAR_LIGAND_ID":"12034","SECONDARY_CAS_RN":"122841-12-7","MESH_SUPPLEMENTAL_RECORD_UI":"C079769"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.9 hours","clearance":"1.77 mL/min/kg","volumeOfDistribution":"0.3 L/kg"},"publicationCount":26,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec 2","pmid":"40985153","title":"Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies.","journal":"The Journal of antimicrobial chemotherapy"},{"date":"2023 Jun 15","pmid":"37184411","title":"In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019.","journal":"Microbiology spectrum"},{"date":"2023 Feb","pmid":"36808887","title":"Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells.","journal":"Clinical and translational medicine"},{"date":"2021 Jun 26","pmid":"34222426","title":"Efficacy of combination of localized closure, ethacridine lactate dressing, and phototherapy in treatment of severe extravasation injuries: A case series.","journal":"World journal of clinical cases"},{"date":"2021 Sep 15","pmid":"34215878","title":"Establishment of epidemiological cut-off values for cefoselis, a new fourth-generation cephalosporin, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis and Pseudomonas aeruginosa.","journal":"The Journal of antimicrobial chemotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Wincef (CEFOSELIS) is a small molecule antibiotic in the cefoselis drug class. It is used to treat bacterial infections, although its specific target and approved indications are unknown. The commercial status of Wincef is unclear, and it is not known whether it is patented or available as a generic. The drug has a half-life of 2.9 hours, but its bioavailability is unknown. Further information on Wincef's development, approval, and safety profile is needed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}